MASH (Metabolic Dysfunction-associated Steatohepatitis) is among the most common indications for liver transplantation.The metabolic syndrome persists after liver transplant and is often further exacerbated among MAFLD patients, thereby leading to recurrence of MAFLD in the allograft. MAFLD is a complex phenotype, dynamic interactions between both genetic and environmental factors are likely to shape disease susceptibility and progression.
Genetic and epidemiological studies, indicates strong heritability of hepatic fat content.Family studies demonstrate that first degree relatives of patients with MAFLD are at a much higher risk of the disease than the general population.Most of the data available is regarding Deceased Donor Liver Transplant and Western population.Most studies have studied single gene variant but fatty liver is a polygenic trait.No study was done exclusively in MASH recipients.
In this study we aim to study the effect of recipient and donor PNPLA3, MBOAT7 gene variations, and other clinical \& laboratory data on graft liver steatosis in liver transplant recipients. We also propose to compare the outcomes of genetically related donors vs unrelated donors, to know the influence of genetic factors vis-a-vis environmental factors.
All LDLT recipients with MASH related CLD and their donors who underwent their surgery at ILBS at least 3 years prior to the onset of this study.
Pediatric (<18 years)
Transplants for ALF/ ACLF
All LDLT recipients with MASH related CLD and their donors who underwent their surgery at ILBS at least 3 years prior to the onset of this study.
Case-only
Prospective
Not listed
PNPLA3 and MBOAT7 gene polymorphisms
To assess the impact of donor and recipient PNPLA3 and MBOAT7 gene polymorphisms on the development and severity of graft steatosis following Living Donor Liver Transplantation
Click on the lead sponsor to view all of their trials.
